#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4226	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1894	385.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1645	1645	T	417	T	231	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4226	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1894	385.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1379	1379	C	467	C	270	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7670	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3238	394.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1516	1516	A	345	A	210	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7670	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3238	394.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2150	2150	C	389	C	222	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7670	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3238	394.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2224	2224	A	387	A	227	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7670	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3238	394.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2776	2776	C	408	C	235	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	27	282	folP	852	852	99.88	folP.l15.c4.ctg.1	1543	31.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	2491	98.56	gyrA.l15.c4.ctg.1	2683	43.4	0	.	p	.	0	M773R	NONSYN	2317	2319	ATG	2503	2505	AGG	6;6;6	A;G,T;G	3;1,2;3	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	2491	98.56	gyrA.l15.c4.ctg.1	2683	43.4	0	.	p	.	0	D778A	NONSYN	2332	2334	GAC	2518	2520	GCC	2;2;2	G;C,A;C	0;0,2;1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	2491	98.56	gyrA.l15.c4.ctg.1	2683	43.4	0	.	p	.	0	V782D	NONSYN	2344	2346	GTC	2530	2532	GAC	2;2;2	G;A;C	1;0;0	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	2491	98.56	gyrA.l15.c4.ctg.1	2683	43.4	0	.	p	.	0	S783R	NONSYN	2347	2349	AGC	2533	2535	CGC	2;2;2	C;G;C	0;1;1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	2491	98.56	gyrA.l15.c4.ctg.1	2683	43.4	0	.	p	.	0	L784fs	FSHIFT	2350	2350	C	2536	2536	C	2	C	1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	2491	98.56	gyrA.l15.c4.ctg.1	2683	43.4	1	SNP	p	S91F	0	.	.	271	273	TCC	457	459	TCC	53;53;54	T;C;C	30;31;31	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	2491	98.56	gyrA.l15.c4.ctg.1	2683	43.4	1	SNP	p	D95N	0	.	.	283	285	GAC	469	471	GAC	60;60;60	G;A;C	33;33;33	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	2491	98.56	gyrA.l15.c4.ctg.1	2683	43.4	1	SNP	p	D95G	0	.	.	283	285	GAC	469	471	GAC	60;60;60	G;A;C	33;33;33	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	798	gyrA	2751	327	100.0	gyrA.l15.c4.ctg.2	884	21.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	150	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1194	19.6	0	.	p	.	0	A39T	NONSYN	115	117	GCC	400	402	ACC	33;33;29	A;C;C	18;20;18	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	150	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1194	19.6	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	598	600	CAC	35;33;34	C;A;C	19;15;18	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	150	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1194	19.6	0	.	p	.	0	E117N	NONSYN	349	351	GAA	634	636	AAA	29;29;29	A;A;A	20;19;17	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	150	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1194	19.6	1	SNP	p	G45D	0	.	.	133	135	GGC	418	420	GGC	27;27;27	G;G;C	17;17;17	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	96	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	714	22.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	710	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3031	38.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1555	1557	GCA	43;43;43	G;C;A	25;22;25	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	710	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3031	38.4	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2038	2040	ATT	46;44;44	A;T;T	26;23;24	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	710	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3031	38.4	1	SNP	p	D86N	0	.	.	256	258	GAC	508	510	GAC	49;49;49	G;A,G;C	29;27,1;29	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	710	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3031	38.4	1	SNP	p	S87R	0	.	.	259	261	AGT	511	513	AGT	47;47;47	A;G;T	27;29;26	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	710	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3031	38.4	1	SNP	p	S87W	0	.	.	259	261	AGT	511	513	AGT	47;47;47	A;G;T	27;29;26	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	710	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3031	38.4	1	SNP	p	S87I	0	.	.	259	261	AGT	511	513	AGT	47;47;47	A;G;T	27;29;26	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	710	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3031	38.4	1	SNP	p	S88P	0	.	.	262	264	TCC	514	516	TCC	47;48;48	T;C;C	28;27;28	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	263	584	parE	1986	1982	99.95	parE.l15.c17.ctg.1	2153	42.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1399	1401	GGC	40;40;40	G;G;C	24;24;24	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	263	584	parE	1986	190	100.0	parE.l15.c17.ctg.2	458	14.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1206	1208	GCA	76;75;75	G;C;A	44;43;44	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1209	1211	ATC	77;77;77	A;T;C	46;44;46	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1221	1223	GTG	81;81;81	G;T;G,C	47;45;48,1	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1221	1223	GTG	81;81;81	G;T;G,C	47;45;48,1	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1725	1727	ACC	45;45;45	A;C;C	30;33;31	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1779	1781	GCG	45;45;45	G;C;G	29;28;30	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1779	1781	GCG	45;45;45	G;C;G	29;28;30	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1902	1904	GGT	46;45;45	G;G;T	30;30;28	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1911	1913	GGC	41;41;35	G;G;C	27;27;21	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	708	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2235	53.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1929	1931	CCG	33;32;32	C;C;G	20;22;17	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1306	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3233	65.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	414	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1783	39.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	452	452	C	28	C	16	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1673	43.3	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	689	691	CAA	48;46;46	C;A;A	29;29;29	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1673	43.3	0	.	p	.	0	E212G	NONSYN	634	636	GAA	896	898	GGT	61;63;60	G;G;T	39;40;39	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1673	43.3	0	.	p	.	0	H213G	NONSYN	637	639	CAT	899	901	GGT	60;61;61	G;G;T	37;39;36	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1673	43.3	0	.	p	.	0	V215D	NONSYN	643	645	GTT	905	907	GAT	65;64;64	G;A,C;T	40;40,1;41	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1673	43.3	0	.	p	.	0	I218M	NONSYN	652	654	ATC	914	916	ATG	66;66;66	A;T;G	41;38;40	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1673	43.3	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1031	1033	AAG	79;79;79	A;A;G	43;43;41	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1673	43.3	1	SNP	p	G120K	0	.	.	358	360	GGC	620	622	GGC	41;41;40	G;G;C	28;26;26	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	N118T	NONSYN	352	354	AAC	11	13	ACC	2;2;2	A;C;C	0;0;0	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	I138S	NONSYN	412	414	ATC	71	73	AGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	86	88	CAA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	G160C	NONSYN	478	480	GGC	137	139	TGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	S175A	NONSYN	523	525	TCA	182	184	GCA	1;1;1	G,T;C;A	0,1;1;1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	E212G	NONSYN	634	636	GAA	293	295	GGT	6;6;6	G;G;T	3;3;3	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	H213G	NONSYN	637	639	CAT	296	298	GGT	4;4;4	G;G;T	2;2;2	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	V215D	NONSYN	643	645	GTT	302	304	GAT	4;4;4	G;A;T	2;2;2	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	I218M	NONSYN	652	654	ATC	311	313	ATG	4;4;4	A;T;G	2;2;2	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	0	.	p	.	0	N238fs	FSHIFT	712	712	A	371	371	A	2	A	1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	527	426	porB1b	1047	464	96.77	porB1b.l6.c30.ctg.2	463	2.1	1	SNP	p	G120K	0	.	.	358	360	GGC	17	19	GGC	2;2;2	G;G;C	0;0;0	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1964	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	4772	72.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1957	1959	CAT	84;83;83	C;A;T	51;50;50	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	154	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1219	23.5	1	SNP	p	V57M	0	.	.	169	171	GTG	741	743	GTG	50;49;49	G;T;G	31;30;30	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
